索拉非尼治疗晚期肾癌不良反应的观察及护理

Clinical observation and nursing care of adverse reactions of sorafenib to treat patients with renal cancer in advanced stage

目的探讨索拉非尼治疗晚期肾癌的护理体会。方法总结2010年9月至2012年9月应用索拉非尼治疗的56例晚期肾癌患者的随访资料。结果 56例患者均出现不同程度和不同表现的可耐受的不良反应。结论索拉非尼对晚期肾癌的病情控制有较好的效果,而且其毒副作用相对较轻,通过严格随访,积极预防及对症护理,服药后安全性良好,患者多可耐受。

Objective To discuss the nursing experiences on the targeted therapy for advanced renal cell carcinoma using sorafenib. Methods A total of 56 cases （31 men and 25 women ranging in age from 39 to 78, average 56） with advanced renal cell carcinoma were treated with sorafenib be- tween September 2010 and September 2012. The clinical date were summarized. The adverse reac tions and nursing treatment methods of sorafenib were discussed. Results Three cases were died （one died at the start of the treatment, two died of a cerebral vascular accident）, the median treat- ment time of the 53 patients was 24 cycles （24 months）. 3. 77% （2/53） complete remission, 20.76% （11/53） partial remission, 62.26% （33/53） in stable condition, 13.21%（7/53） progres- sion, the objective response rate is 24. 53% （13/53） and the control rate is 86.79% （46/53）. 84.91% （45/53） occurred hand foot syndrome, 52. 83% （28/53） occurred diarrhea, 24. 53% （13/53） occurred anorexia, 7.55% （4/53） with nausea and vomiting, 22. 64% （12/53） occurred hypertension. Conclusions The patients with advanced renal cell carcinoma treated with sorafenib can achieve better control effect, the toxic and side effect is relatively small, through strict follow- up, active prevention and nursing, patients can tolerant the adverse reactions well and improve the quality of their life.